LRRFIP2

Across TCGA pan-cancer cohorts, LRRFIP2 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated LRRFIP2 data layer compared with 25 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher LRRFIP2 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated LRRFIP2 expression acts as an unfavorable survival marker, although some lineages such as PDAC and CCRCC show a favorable association.

PDAC, GBM, and CCRCC are the cancer types where LRRFIP2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Quartile	II,III,IV	0.933	0.492	.008	32	view →
GBM	DFS	Tertile	All	0.615	0.808	.003	18	view →
CCRCC	OS	Median	All	0.950	0.834	.043	2	view →
UCEC	DFS	Quartile	All	1.000	0.823	.013	2	view →
LUAD	OS	Tertile	III,IV	0.288	0.774	.047	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

LRRFIP2–PDAC (DFS)

Open the PDAC breakdown →